Sökning: id:"swepub:oai:DiVA.org:oru-110611" >
Intraoperative Radi...
Intraoperative Radiation Therapy Delivered by Brachytherapy in Breast Cancer : An Interim Analysis of a Phase 2 Trial
-
- Wickberg, Åsa, 1972- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Surgery
-
- Prag, Clara (författare)
- Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Örebro, Sweden
-
- Valachis, Antonis, 1984- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology
-
visa fler...
-
- Karlsson, Leif (författare)
- Department of medical Physics, Örebro University Hospital, Örebro, Sweden
-
- Johansson, Bengt, 1958- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology
-
visa färre...
-
(creator_code:org_t)
- CIG Media Group, LP, 2024
- 2024
- Engelska.
-
Ingår i: Clinical Breast Cancer. - : CIG Media Group, LP. - 1526-8209 .- 1938-0666. ; 24:3, s. 243-252
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Intraoperative breast cancer radiotherapy (IORT) offers an alternative to external beam radiotherapy (EBRT) after breast-conserving surgery (BCS). The Intraoperative brachytherapy (IOBT) trial applies high dose rate (HDR) brachytherapy with a new applicator prototype as IORT after BCS. In this interim analysis of the IOBT trial, we present the oncological safety and toxicity of the method.METHODS: Eligible patients were women, ≥ 50 years old with an unifocal nonlobular, estrogen-receptor-positive, HER2-negative breast cancer, cN0, ≤ 3 cm, treated with BCS and sentinel node biopsy (SNB). Toxicity was registered according to the LENT-SOMA scale. Cumulative incidence of local (LR) and regional recurrence (RR) were calculated through cumulative incidence function whereas overall survival (OS) was illustrated through Kaplan-Meier curve.RESULTS: Until February 2023, 155 women (median age 68 years) were included in the trial. Twenty-nine women (18.7%) received supplemental EBRT, mostly due to positive SNB. Three-year cumulative incidence of LR and RR were 1.0% (CI 95 % 0.1%-2.3%) and 2.1% (CI 95% 0.8%-4.2%) respectively. Five- year cumulative incidence of LR and RR were 3.9% (CI 95% 1.8%-6.4%) and 2.1% (CI 95% 0.8%-4.2%) respectively. Five-year OS was 96.3% (CI 95% 93.6%-98.4%). Side effects were limited, low grade, and transient.CONCLUSION: Acknowledging the short median follow-up time at interim analysis, our initial results indicate that delivering IORT through HDR brachytherapy in carefully selected breast cancer patients is feasible and oncological safe so far. A long-term follow-up is essential to confirm the initial results.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Breast-conserving surgery
- Endocrine therapy
- Intraoperative brachytherapy
- Local recurrence
- Partial breast irradiation
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas